



# OnDemand: TOS 2022 40<sup>th</sup> Annual Scientific Meeting Continuing Medical Education Information for Learners

## Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this internet enduring material for a maximum of 95.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*ACCME activity ID 202350465*

## Important Dates for On-Demand Course (Enduring Material)

Date of Release: January 4, 2023

Date of Termination: December 31, 2023

## Learning Objectives

1. Apply the latest recommendations for evaluation and treatment; tailor intervention strategies based on patient characteristics such as age or metabolic or behavioral phenotype; understand the differences between weight loss and weight loss maintenance.
2. Understand the evidence-based science regarding neuroendocrine, environmental, endocrine, microbiota and/or cognitive behavioral mechanisms regulating energy balance and body weight. Apply that knowledge to develop and implement treatment options for adults and pediatric patients with overweight, obesity or obesity-related co-morbidities.

3. Implement appropriate strategies for diagnosing adolescent and pediatric obesity, evaluate current treatment options and emerging therapeutics and provide care and treatment to adolescent and pediatric patients accordingly. Teach evidence-based strategies for obesity prevention in the pediatric and adolescent population.
4. Apply lessons learned about the impact of: nutrition and obesity initiatives to reduce health disparities, and federal nutrition and obesity policies on health disparities.
5. Apply new knowledge related to dietary intervention and physical activity from the perspectives of Metabolism and Integrative Physiology, Neuroscience, Intervention and Clinical Studies, Population Health, Clinical/Professional Practice, and Policy/Public Health.
6. Incorporate knowledge about coding for reimbursement into the clinical practice of health care providers to support their ability to treat the underlying disease of overweight and obesity. Incorporate knowledge about best practices to develop and run effective clinics that treat overweight and obesity.

## Commercial Support

The blended activity where this enduring material was recorded received educational grants in partial support of the conference from Pfizer, Inc., Rhythm Pharmaceuticals, Inc., and Lilly.

## Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities<sup>1</sup> (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed. TOS requires additional disclosures beyond the ACCME definition of an ineligible company. These include food, weight loss, and supplement industry disclosures. In the list below, the nature of the relationship and company are followed by the industry of that company.

---

<sup>1</sup> An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: <https://accme.org/faq/what-accmes-definition-ineligible-company>

## Chairs:

At TOS activities, course/session chairs are responsible for timekeeping, introductions, housekeeping announcements, and presenting audience questions to speakers. TOS has determined that chairs do not have the ability to influence content. Accordingly, TOS does not collect, mitigate, or disclose relevant financial relationships of chairs (unless they have a dual role as a planner or speaker).

## Panelists:

Panelists are speakers who speak without presenting slides in a portion of a session or course. As speakers, they are required to disclose, and their relevant financial relationships are listed below. All speakers - with or without relevant financial relationships, with or without slides - are advised, and subsequently attest that "The content and/or presentation of the information with which I am involved will promote quality or improvements in health care and will not promote a specific proprietary business interest or a commercial interest (including ACCME-defined ineligible companies). Content for this activity, including any presentation of therapeutic options, will be balanced, evidence-based and commercially unbiased."

## Speaker Disclosures:

Name of Presenter	Relevant Financial Relationships
Mahmoud Abulmeaty, MD, FACN	No Relevant Financial Relationships
Ted Adams, PhD	No Relevant Financial Relationships
Liliana Aguayo, PhD, MPH	No Relevant Financial Relationships
Muzayyana Akhmadjonova, MD	No Relevant Financial Relationships
Michael Albert, MD	Consultant relationship with Gelesis (Medical Device) and Novo Nordisk (Pharmaceuticals); Advisor and Stock Options relationship with Elo Health (Supplement)
Jaclyn Albin, MD, CCMS, DipABLM	No Relevant Financial Relationships
Amber Alhadeff, PhD	No Relevant Financial Relationships
David Allison, PhD, FTOS	Consultant relationship with Alkermes Inc. (Pharmaceuticals); Kaleido Biosciences (Pharmaceuticals); and Novo Nordisk (Pharmaceuticals)  Researcher relationship with Eli Lilly and Company (Pharmaceuticals); Soleno Therapeutics (Pharmaceuticals); WW (Weight Management/Medical Food); American Egg Board (Non-medical Food); Haas Avocado Board (Non-medical Food); Mars Inc. (Non-medical Food); Alliance for Potato Research and Education (Non-medical Food); and National Cattlemen's Beef Association (Non-medical Food)  Stock options relationship with Big Sky Health (Medical Device)  Advisor relationship with Novo Nordisk (Pharmaceuticals) and Big Sky Health (Medical Device)

Name of Presenter	Relevant Financial Relationships
Kelly Allison, PhD	No Relevant Financial Relationships
Saleh Alqahtani, MD	No Relevant Financial Relationships
Mark Andermann, PhD	No Relevant Financial Relationships
John Apolzan, PhD, FTOS	Researcher relationship with WW (Weight Management/Medical Food) and Mizkan Holdings Co., Ltd.(Non-medical Food)
Yeka Aponte, PhD	No Relevant Financial Relationships
Bradley Appelhans, PhD	No Relevant Financial Relationships
Jamy Ard, MD	<p>Advisor relationship with Level2 (Weight Management).</p> <p>Consultant relationship with Calibrate (Weight Management); Eli Lilly (Pharmaceuticals); Regeneron (Medical Device); Novo Nordisk (Pharmaceuticals); and Brightseed (Biomedical).</p> <p>Researcher relationship with Boehringer Ingelheim (Pharmaceuticals); Epitomee, Inc.(Medical Device); UnitedHealth Group (Biomedical); KVKTech (Pharmaceuticals); WW (Weight Management/Medical Food); and Nestle Healthcare Nutrition (Medical Food).</p>
Kirsten Arm, MPH, RDN	No Relevant Financial Relationships
Sarah Armstrong, MD	No Relevant Financial Relationships
Beyza Aydin, MD	No Relevant Financial Relationships
Victoria Bae-Jump, PhD, MD	Researcher relationship with Merck (Pharmaceutical/Biomedical); Chimerix (Pharmaceutical/Biomedical) and Genentech (Pharmaceuticals); Independent Contractor relationship with Sphaera (Pharmaceuticals) and Cardero (Pharmaceuticals); Consultant relationship with Eisai (Pharmaceuticals)
Simar Bajaj	No Relevant Financial Relationships
Geoff Ball, PhD, RD, FTOS	Advisor relationship with Novo Nordisk Canada (Pharmaceuticals)
Sarah Barlow, MD, MPH	No Relevant Financial Relationships
Simon Barquera, MD, MS, PhD, FTOS	No Relevant Financial Relationships
Louise Baur	Speaker and Advisor relationships with Novo Nordisk (Pharmaceuticals)
Jennifer Bea, PhD	Researcher relationship with Disarm Therapeutics (Pharmaceuticals)
Tiffani Bell Washington, MD, MPH, FAPA, DABOM, DABLM	No Relevant Financial Relationships
Jerica Berge, PhD, MPH, LMFT	No Relevant Financial Relationships
Hans-Rudolf Berthoud, PhD	Consultant relationship with Novo Nordisk (Pharmaceuticals)
Dan Bessesen, MD, FTOS	Speaker relationship with Novo Nordisk (Pharmaceuticals); Consultant relationship with Lilly (Pharmaceuticals)
J. Nicholas Betley, PhD	No Relevant Financial Relationships
Diego Bohorquez, PhD	No Relevant Financial Relationships
Sarah Borengasser, PhD	No Relevant Financial Relationships

Name of Presenter	Relevant Financial Relationships
Tito Borner, PhD	No Relevant Financial Relationships
Molly Bray, PhD	No Relevant Financial Relationships
Kristal Brown, PhD, MSPH	No Relevant Financial Relationships
Barto Burguera, MD, PhD	Researcher relationship with Novo Nordisk (Pharmaceuticals)
Ryan Burns, BAppSc, MChD, MPH	Publicly-traded Stock relationship with Eli Lilly (Pharmaceuticals)
Cailin Caspi, ScD	No Relevant Financial Relationships
Omni Cassidy, PhD	No Relevant Financial Relationships
Patrick Catalano, MD	No Relevant Financial Relationships
Delwyn Catley, PhD	No Relevant Financial Relationships
John Cawley, PhD	Consultant relationship with Novo Nordisk (Pharmaceuticals)
Jean-Philippe Chaput, PhD	No Relevant Financial Relationships
Liuyi Chen	No Relevant Financial Relationships
Julie Christianson, PhD	Researcher relationship with Biogen (Pharmaceuticals)
Lizeth Cifuentes, MD	No Relevant Financial Relationships
Jaime Coffino, PhD, MPH	No Relevant Financial Relationships
Anita Courcoulas, MD, MPH, FACS	No Relevant Financial Relationships
Seth Creasy, PhD	No Relevant Financial Relationships
Melanie Cree-Green	Consultant relationship with Pollie (Medical Device)
Noe Crespo, PhD	No Relevant Financial Relationships
Hassan Dashti, PhD, RD	No Relevant Financial Relationships
Ashlesha Datar, PhD	No Relevant Financial Relationships
Jaimie Davis, RD, PHD	No Relevant Financial Relationships
Bart de Jonghe, PhD	Researcher relationship with Eli Lilly (Pharmaceuticals)
Nikhil Dhurandhar, MS, LCEH, PhD, FTOS	Researcher relationship with The Beef Checkoff (Non-medical Food); Insparin (Pharmaceuticals); Novo Nordisk (Pharmaceuticals); and American Egg Board (Non-medical Food)  Advisor relationship with Medifast (Weight Management/Medical Food)
Adeline Divoux, PhD	No Relevant Financial Relationships
Emily Duffy, MPH	No Relevant Financial Relationships
Wesley Dutton, MD	No Relevant Financial Relationships
Leonard Egede, MD, MS	No Relevant Financial Relationships
Dawn Eichen, PhD	No Relevant Financial Relationships
Ihuoma Eneli, MD, MS	Researcher relationship with Rhythm Pharmaceuticals (Pharmaceuticals)
Melissa Erickson, PhD	No Relevant Financial Relationships
Mary Evans, PhD	No Relevant Financial Relationships

Name of Presenter	Relevant Financial Relationships
Ismaa Sadaf Farooqi, MBChB (Hons), PhD, FRCP, FMedSci, DSc	Consultant relationship with Rhythm Pharmaceuticals (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). Speaker relationship with Eli Lilly (Pharmaceuticals).
Cristina Fernandez, MD	No Relevant Financial Relationships
Lauren Fiechtner, MD, MPH	No Relevant Financial Relationships
Alison Field, ScD, FTOS	No Relevant Financial Relationships
David Fields, PhD	No Relevant Financial Relationships
Stephanie Fitzpatrick, PhD	Employee relationship with WW International Inc. (Weight Management/Medical Food) Note: This financial conflict is not relevant because the content of session is not related to the business lines or products of her employer.
Kathryne Foos	No Relevant Financial Relationships
Evan Forman, PhD	Advisor relationship with Nutrisystem (Weight Management/Medical Food)
Vida Forouhar, BSc	No Relevant Financial Relationships
Samantha Fortin, PhD	No Relevant Financial Relationships
Carolynn Francavilla Brown, MD, D-ABOM, FOMA	Independent Contractor relationship with Optavia (Medical Food)  Publicly-traded Stock relationship with Eli Lilly (Pharmaceuticals)
Jennifer Franceschelli Hosterman, DO, FAAP	No Relevant Financial Relationships
Kelsey Gabel, PhD, RD	No Relevant Financial Relationships
Christopher Gardner, PhD	Initial report: No Relevant Financial Relationships Note: During his presentation, Dr. Gardner verbally added a Consultant relationship with Zoe (Diagnostic Laboratory)
Ariana Garza, MPH	No Relevant Financial Relationships
Laura Gibson, PhD	No Relevant Financial Relationships
Erin Giles, PhD	No Relevant Financial Relationships
Alyson Goodman, MD, MPH	No Relevant Financial Relationships
Bret Goodpaster, PhD	No Relevant Financial Relationships
Johanne Gormsen, MD	No Relevant Financial Relationships
Marcio Griebeler, MD	Contracted Research relationship with Novo Nordisk (Pharmaceuticals)
Karen Grothe, PhD	No Relevant Financial Relationships
Anna Grummon, PhD, MSPH	No Relevant Financial Relationships
Matthew Haemer, MD, MPH	No Relevant Financial Relationships
Erin Hager, PhD	No Relevant Financial Relationships
Sarah Hampl, MD	No Relevant Financial Relationships
Joan Han, MD	Researcher relationship with Rhythm Pharmaceuticals (Pharmaceuticals)

Name of Presenter	Relevant Financial Relationships
Kristal Hartman	Patient Steering Committee relationship with Pfizer (Pharmaceuticals)
Anna Hayes, PhD	No Relevant Financial Relationships
Bill Heerman, MD MPH	No Relevant Financial Relationships
Sharon Herring, MD, MPH	No Relevant Financial Relationships
Emily Hill, PhD, RDN	No Relevant Financial Relationships
Jennie Hill, PhD	No Relevant Financial Relationships
Joseph Hill, MD, PhD	No Relevant Financial Relationships
Emily Hohman, PhD	No Relevant Financial Relationships
Jonathan Hommel, PhD	No Relevant Financial Relationships
Denise Houston, PhD, RD	No Relevant Financial Relationships
Carrie Howell, PhD	No Relevant Financial Relationships
Sophia Hua, PhD, MPH	No Relevant Financial Relationships
Autumn Hullings, MPH	No Relevant Financial Relationships
Roberta Ienca, MD	No Relevant Financial Relationships
Angela Incollingo Rodriguez, PhD	No Relevant Financial Relationships
Chandra Jackson, PhD, MS	No Relevant Financial Relationships
Bhav Jain	No Relevant Financial Relationships
Danielle Jake-Schoffman, PhD	No Relevant Financial Relationships
John Jakicic, PhD, FTOS, FACSM	Advisor relationship with Wondr Health Inc. (Weight Management); and WW International Inc. (Weight Management/Medical Food); Researcher relationship with Epitomee Medical Inc. (Pharmaceuticals); Consultant relationship with Educational Initiatives Inc. (Weight Management)
Ania Jastreboff, MD, PhD	<p>Advisor relationship with Novo Nordisk (Pharmaceuticals); Eli Lilly (Pharmaceuticals); Boehringer Ingelheim (Pharmaceuticals); Pfizer (Pharmaceuticals); Rhythm Pharmaceuticals (Pharmaceuticals); WW (Weight Management/Medical Food); Intellihealth (Weight Management Telehealth-TOS conflict).</p> <p>Consultant relationship with Scholar Rock (Pharmaceuticals).</p> <p>Researcher relationship with Novo Nordisk (Pharmaceuticals).</p> <p>Stock Options relationship with IntelliHealth (Weight Management Telehealth-TOS conflict).</p>
Matthew Jeans, MS, MM	No Relevant Financial Relationships
Hiba Jebeile, PhD APD	No Relevant Financial Relationships
Elissa Jelalian, PhD	Corporate Advisory Board relationship with WW (Weight Management/Medical Food)
Veronica Johnson, MD, FAAP	Advisor relationship with Novo Nordisk (Pharmaceuticals)
Bradley Johnston, PhD	No Relevant Financial Relationships

Name of Presenter	Relevant Financial Relationships
Scott Kahan, MD, MPH, FTOS	<p>Advisor relationship with Lilly (Pharmaceuticals); Currax (Pharmaceuticals); and Gelesis (Medical Device).</p> <p>Consultant relationship with Vivus (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals).</p>
Kathryn Kaiser, PhD	No Relevant Financial Relationships
Lee Kaplan, MD, PhD, FTOS	<p>Consultant relationship with Altimmune, Amgen, Boehringer Ingelheim, Gilead Sciences, Lilly, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, Xeno Biosciences (All Pharmaceuticals).</p> <p>Consultant relationship with Johnson &amp; Johnson, Gelesis, GI Windows, GI Dynamics (all Medical Device).</p> <p>Consultant relationship with Intellihealth and Optum (Both Weight Management).</p>
Erica Kenney, ScD, MPH	No Relevant Financial Relationships
Wendy King, PhD	No Relevant Financial Relationships
Eliza Kinsey, PhD, MPH	No Relevant Financial Relationships
Samuel Klein, MD	<p>Scientific Advisory Board relationship with Merck (Pharmaceuticals) and Altimmune (Pharmaceuticals).</p> <p>Consultant relationship with Lilly (Pharmaceuticals); Alnyln (Pharmaceuticals); and B2M (Medical Device).</p>
Christopher Kline, PhD	No Relevant Financial Relationships
Kai Ling Kong, PhD	No Relevant Financial Relationships
Theodore Kyle, RPh, MBA	<p>Advisor relationship with Gelesis (Pharmaceuticals) and Nutri System (Weight Management/Medical Food).</p> <p>Speaker relationship with Johnson &amp; Johnson (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals).</p>
Matthew Landry, PhD, RDN	No Relevant Financial Relationships
Helena Laroche, MD	Publicly-traded Stock relationship with Walgreens (Pharmaceuticals) and Viartis (Pharmaceuticals)
Maren Laughlin, PhD	No Relevant Financial Relationships
Carl Lavie, MD	Speaker relationship with PAI Health (Medical Device)
Elizabeth Lawson, MD, MMSc	<p>Stock Options relationship with Oxytocin Therapeutics Inc. (Pharmaceuticals);</p> <p>Advisor relationship with Oxytocin Therapeutics Inc. (Pharmaceuticals);</p> <p>Researcher relationship with Tonix Pharmaceuticals (Pharmaceuticals)</p>



Name of Presenter	Relevant Financial Relationships
Kristina Lewis, MD, MPH, SM	No Relevant Financial Relationships
Li Li	No Relevant Financial Relationships
Marissa Lightbourne, MD, MPH	No Relevant Financial Relationships
Shuhao Lin	No Relevant Financial Relationships
Karen Lindsay, PhD, RDN	No Relevant Financial Relationships
Sheridan Littleton, BS	No Relevant Financial Relationships
Holly Lofton, MD, DABOM	<p>Advisor relationship with Novo Nordisk (Pharmaceuticals) and Currax Inc (Pharmaceuticals).</p> <p>Speaker relationship with Novo Nordisk (Pharmaceuticals).</p> <p>Researcher relationship with Novo Nordisk (Pharmaceuticals) and Eli Lilly (Pharmaceuticals).</p>
John Long	No Relevant Financial Relationships
Mette Ludwig, PhD	No Relevant Financial Relationships
Andrew Lutkewitte, PhD	No Relevant Financial Relationships
Virgine Mansuy-Aubert, PhD	No Relevant Financial Relationships
Patricia Markby	No Relevant Financial Relationships
Stephanie Mayne, PhD, MHS	No Relevant Financial Relationships
Kelsey McAlister	No Relevant Financial Relationships
Jeremy McConnell, MD, FOMA	Speaker relationship with Novo Nordisk (Pharmaceuticals)
Lacey McCormack, PhD, MPH, RD	No Relevant Financial Relationships
Ying Meng, PhD, RN	No Relevant Financial Relationships
Jacob Mey, PhD, RD	No Relevant Financial Relationships
Elizabeth Mietlicki-Baase, PhD	No Relevant Financial Relationships
Iva Miljkovic, MD, PhD, FAHA	No Relevant Financial Relationships
Nia Mitchell, MD, MPH	No Relevant Financial Relationships
Violeta Moize Arcone, RD, PhD	No Relevant Financial Relationships
Kerrie Moreau, PhD	No Relevant Financial Relationships
Julia Mueller, PhD	No Relevant Financial Relationships
Aviva Musicus, ScD	No Relevant Financial Relationships
Spencer Nadolsky, DO, Dipl. ABOM and ABCL	No Financial Relationships Relevant per ACCME standards. Ownership of GetLeanRx Consulting LLC (Weight Management-TOS conflict)

Name of Presenter	Relevant Financial Relationships
Patty Nece, JD	Consultant relationship with Novo Nordisk (Pharmaceuticals)
Angela Odoms-Young, PhD	No Relevant Financial Relationships
Ashleigh Oliveira	No Relevant Financial Relationships
Madeleine Oudin, PhD	No Relevant Financial Relationships
Jaume Padilla, PhD	No Relevant Financial Relationships
Tusharkumar Patel, PhD	No Relevant Financial Relationships
Elizabeth Paul	No Relevant Financial Relationships
M. Yanina Pepino, PhD	No Relevant Financial Relationships
Michael Perri, PhD	No Relevant Financial Relationships
Courtney Peterson, PhD	No Relevant Financial Relationships
Joshua Petimar, ScD	No Relevant Financial Relationships
Sean Phelan, PhD, MPH	No Relevant Financial Relationships
Chantal Pileggi, PhD	No Relevant Financial Relationships
Monique Potvin Kent, PhD	No Relevant Financial Relationships
Lisa Powell, PhD	No Relevant Financial Relationships
Richard Pratley, MD	Researcher relationship with Hanmi Pharmaceutical Co. (Pharmaceuticals); Novo Nordisk (Pharmaceuticals); Metaventon (Pharmaceuticals); and Poxel (Pharmaceuticals)
John Prom, BS	No Relevant Financial Relationships
Lauren Ptomey, PhD	No Relevant Financial Relationships
Jonathan Purnell, MD, FTOS	Consultant relationship with Novo Nordisk (Pharmaceuticals); Boehringer Ingelheim (Pharmaceuticals); and Luciole (Pharmaceuticals)
David Raubenheimer, PhD	No Relevant Financial Relationships
Eric Ravussin, PhD	Researcher relationship with Eli Lilly (Pharmaceuticals); Novartis (Pharmaceuticals); and Sanofi-Avantis (Pharmaceuticals).  Consultant relationship with Eli Lilly (Pharmaceuticals); Merck (Pharmaceuticals); Amway (Supplement); Kintai Therapeutics (Biomedical); YSOPIA (Biomedical).
Hollie Raynor, PhD	No Relevant Financial Relationships
Hollie Raynor, PhD	No Relevant Financial Relationships
Leanne Redman, PhD, FTOS	No Relevant Financial Relationships
Andrea Richardson, PhD, MPH	No Relevant Financial Relationships
Thomas Robinson, MD, MPH, FTOS	Advisor relationship with WW International Inc. (Weight Management/Medical Food)
Griffin Rodgers, MD, MACP	No Relevant Financial Relationships
Renee Rogers, PhD	Consultant relationship with Wondr Health (Weight Management)
Maria Romanova, MD	No Relevant Financial Relationships
Cara Ruggiero, PhD, RD	No Relevant Financial Relationships

Name of Presenter	Relevant Financial Relationships
Donna Ryan, MD, FTOS, MABOM	<p>Advisor relationship with Altimmune (Pharmaceuticals); Alyvent (Weight Management); Amgen (Pharmaceuticals); Boeringer Ingelheim (Pharmaceuticals); Calibrate (Weight Management); Epitomee (Medical Device); Gila Therapeutics (Pharmaceuticals); Lilly (Pharmaceuticals); Novo Nordisk (Pharmaceuticals); Phenomix (Biomedical); Real Appeal (Weight Management); Sanofi (Pharmaceuticals); Wondr Health (Weight Management); YSOPIA (Pharmaceuticals); and Zealand (Pharmaceuticals).</p> <p>Consulting Fee relationship with Scientific Intake (Medical Device) and Xeno Bioscience (Pharmaceuticals).</p> <p>Data Safety Monitoring Board for Rhythm (setmelanotide) relationship with IQVIA (Biomedical).</p> <p>Steering Committee relationship with Novo Nordisk (Pharmaceuticals).</p> <p>Speaker relationship with IFA Celtic (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals).</p> <p>Stock options relationship with Calibrate (Weight Management); Scientific Intake (Medical Device); Xeno Bioscience (Pharmaceuticals); Roman (Weight Management); and Epitomee (Medical Device).</p>
Amadeo Salvador, PhD	No Relevant Financial Relationships
Sarah Salvy, PhD	No Relevant Financial Relationships
Lee Sanders, MD, MPH	No Relevant Financial Relationships
Shohinee Sarma, MD MPH FRCPC	No Relevant Financial Relationships
David Sarwer, PhD	Consultant relationship with NovoNordisk (Pharmaceuticals) and Ethicon (Medical Device)
Katherine Saunders, MD	No Financial Relationships Relevant per ACCME standards. Ownership/management interest relationship with Intellihealth (Weight Management Telehealth-TOS conflict)
Leah Schumacher, PhD	No Relevant Financial Relationships

Name of Presenter	Relevant Financial Relationships
Randy Seeley, PhD	<p>Advisor relationship with ShouTi Pharma (Pharmaceuticals); Scohia (Pharmaceuticals); and Fractyl (Medical Device).</p> <p>Consultant relationship with Novo Nordisk (Pharmaceuticals).</p> <p>Researcher relationship with Novo Nordisk (Pharmaceuticals); Astra Zeneca (Pharmaceuticals); and Fractyl (Medical Device).</p> <p>Stock Options relationship with Calibrate (Weight Management) and Rewind (Weight Management).</p>
Vasavi Shabrish, PhD	No Relevant Financial Relationships
Alpana Shukla, MD, FTOS	Researcher relationship with Novo Nordisk (Pharmaceuticals)
Roberto Simons-Linares, MD	No Relevant Financial Relationships
Kanakadurga Singer, MD	No Relevant Financial Relationships
Caitlin Smith, PhD	No Relevant Financial Relationships
Diana Soria, MSc, PhD	No Relevant Financial Relationships
Mai Spaulding	No Relevant Financial Relationships
Ruth St Fleur, PhD	No Relevant Financial Relationships
Sarah Stern, PhD	No Relevant Financial Relationships
Marie-Pierre St-Onge, PhD, CCSH, FAHA	<p>Speaker relationship with PharmaVite (Supplement); Consultant relationship with Nestle (Medical Food) and PepsiCo (Non-Medical Food)</p>
Baiyang Sun, MPH	No Relevant Financial Relationships
Marius Svanevik, MD, PhD	No Relevant Financial Relationships
Lindsey Taillie, PhD, MPH	No Relevant Financial Relationships
Alexander Tam, BA	No Relevant Financial Relationships
Deborah Tate, PhD	<p>Advisor relationship with WW (Weight Management/Medical Food) and Wondr Health (Weight Management).</p> <p>Researcher relationship with WW (Weight Management/Medical Food).</p>
Simeon Taylor, MD, PhD	Consultant relationship with Ionis Pharmaceuticals (Pharmaceuticals)
June Tester, MD, MPH	No Relevant Financial Relationships
Christoph Thaiss, PhD	No Relevant Financial Relationships
Gita Thapaliya, PhD	No Relevant Financial Relationships
Diana Thomas, PhD, FTOS	No Relevant Financial Relationships
Karen Tinlin	No Relevant Financial Relationships
Kristy Townsend, PhD	No Relevant Financial Relationships
Gina Tripicchio, PhD, MEd	No Relevant Financial Relationships
Louise Tully, RNutr, PhD	No Relevant Financial Relationships

Name of Presenter	Relevant Financial Relationships
Brie Turner-McGrievy, PhD, MS, RD, FTOS	No Relevant Financial Relationships
Yigit Unlu, MD	No Relevant Financial Relationships
Sarvenaz Vandyousefi, PhD, MS, RD	No Relevant Financial Relationships
Aditi Vasan, MD, MSHP	No Relevant Financial Relationships
Alaina Vidmar, MD	No Relevant Financial Relationships
Thomas Wadden, PhD	Advisor relationship with WW (Weight Management/Medical Food) and Novo Nordisk (Pharmaceuticals).
Monica Wang, ScD	No Relevant Financial Relationships
Leah Whigham, PhD, FTOS	No Relevant Financial Relationships
Gretchen White, PhD	No Relevant Financial Relationships
Elizabeth Widen, PhD, RD	Researcher relationship with Egg Nutrition Center (Non-medical Food) and National Cattlemen's Beef Association (Non-medical Food)
Denise Wilfley, PhD	No Relevant Financial Relationships
Nathan Winn, PhD	No Relevant Financial Relationships
David Wright, PhD	No Relevant Financial Relationships
Marc Wuerdeman, MD	No Relevant Financial Relationships
Holly Wyatt, MD	Ownership of Shakabuku LLC (Weight Management-TOS conflict/not relevant by ACCME standards).  Researcher relationship with Gelesis (Medical Device); Epitomee Medical Ltd (Medical Device); Novo Nordisk (Pharmaceuticals); General Mills (Non-medical Food) and Nationals Cattleman's Beef Association (Non-medical Food).  Royalties relationship with State of Slim book (Weight Management).  Advisor relationship with Gelesis (Medical Device).  Stock Options relationship with Ro (Weight Management).
Chittaranjan Yajnik, MD, FRCP	No Relevant Financial Relationships
Jeffrey Zigman, MD, PhD, FTOS	Publicly-traded Stock relationship with Medtronic (Medical Device); Researcher relationship with Novo Nordisk (Pharmaceuticals); Consultant relationship with Dexcel Pharma (Pharmaceuticals)

**Planner Disclosures:** TOS Annual Meeting Program Committee disclosures:

Name	Planning Committee Role	Relevant Financial Relationships
Allison, Kelly (PhD)	Chair	No Relevant Financial Relationships
White, Ursula (PhD)	Co-Chair	No Relevant Financial Relationships

Name	Planning Committee Role	Relevant Financial Relationships
Brown, Rebecca (MD)	T1: Metabolism/Integrative Physiology Chair	Contracted Research relationship with Regeneron Pharmaceuticals (Pharmaceuticals).  In kind research support relationship with Akcea Therapeutics (Pharmaceuticals) and Amryt Pharma (Pharmaceuticals).
Sparks, Lauren (PhD)	T1: Metabolism/Integrative Physiology Co-Chair	No Relevant Financial Relationships
Allerton, Timothy (PhD, RCEP)	T1: Metabolism/Integrative Physiology	No Relevant Financial Relationships
Rojas-Rodriguez, Raziell (PhD)	T1: Metabolism/Integrative Physiology	No Relevant Financial Relationships
Stewart, Delisha (PhD)	T1: Metabolism/Integrative Physiology	No Relevant Financial Relationships
Wingo, Brooks (PhD)	T1: Metabolism/Integrative Physiology	No Relevant Financial Relationships
Leinninger, Gina (PhD)	T2: Neuroscience Chair	No Relevant Financial Relationships
Noble, Emily (PhD)	T2: Neuroscience Co-Chair	No Relevant Financial Relationships
Alhadeff, Amber (PhD)	T2: Neuroscience	No Relevant Financial Relationships
Sandoval, Darleen (PhD)	T2: Neuroscience	No Relevant Financial Relationships
Thaler, Josh (MD, PhD)	T2: Neuroscience	Publicly-traded stock relationship with Pfizer (Pharmaceuticals)
Lowe, Michael (PhD)	T3: Intervention/Clinical Studies Chair	No Relevant Financial Relationships
Raynor, Hollie (PhD)	T3: Intervention/Clinical Studies Co-Chair	No Relevant Financial Relationships
Catenacci, Victoria (MD)	T3: Intervention/Clinical Studies	No Relevant Financial Relationships
Igel, Leon (MD, FACP, FTOS)	T3: Intervention/Clinical Studies	Salary relationship with Intellihealth (Weight Management Telehealth-TOS conflict, Not an ACCME Conflict)
Jelalian, Elissa (PhD)	T3: Intervention/Clinical Studies	Corporate Advisory Board relationship with WW (Weight Management/Medical Food)
Messiah, Sarah (PhD, MPH, FTOS)	T4: Population Health Chair	No Relevant Financial Relationships
Myers, Candice (PhD)	T4: Population Health Co-Chair	No Relevant Financial Relationships
Arlinghaus, Katherine (PhD, RD)	T4: Population Health	No Relevant Financial Relationships
Saslowsky, David (PhD)	T4: Population Health	No Relevant Financial Relationships

Name	Planning Committee Role	Relevant Financial Relationships
Shams-White, Marissa (PhD, MSTOM, MS, MPH)	T4: Population Health	No Relevant Financial Relationships
Tchang, Beverly (MD)	T5: Clinical/Professional Practice Chair	Consulting Fee relationship with Novo Nordisk (Pharmaceuticals)
Shah, Meera (MD)	T5: Clinical/Professional Practice Co-Chair	No Relevant Financial Relationships
Fitch, Angela (MD)	T5: Clinical/Professional Practice	Corporate Advisory Board relationship with Gelesis (Medical Device); Jenny Craig (Weight Management); and Novo Nordisk (Pharmaceuticals).  Consulting Fee relationship with Ms Medicine (Weight Management).  Stock Options relationship with Found Health (Weight Management) and Suvie (Food).
Goss, Amy (PhD, RDN)	T5: Clinical/Professional Practice	No Relevant Financial Relationships
Griebeler, Marcio (MD)	T5: Clinical/Professional Practice	Contracted Research relationship with Novo Nordisk (Pharmaceuticals)
Pearl, Rebecca (PhD)	T6: Policy/Public Health Chair	No Relevant Financial Relationships
Luke, Amy (PhD)	T6: Policy/Public Health Co-Chair	No Relevant Financial Relationships
Bragg, Marie (PhD)	T6: Policy/Public Health	No Relevant Financial Relationships
Elbel, Brian (PhD, MPH)	T6: Policy/Public Health	No Relevant Financial Relationships
Musicus, Aviva (ScD)	T6: Policy/Public Health	No Relevant Financial Relationships
Comuzzie, Anthony (PhD, FTOS)	TOS CEO	No Relevant Financial Relationships
Bessesen, Dan (MD, FTOS)	TOS President (Governance Liaison)	Speaker relationship with Novo Nordisk (Pharmaceuticals).  Consultant relationship with Lilly (Pharmaceuticals).

**Reviewer Disclosures:** No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee. Two members of the committee, Alpana Shukla and Meera Shaw, stepped down from the committee when they developed a conflict *after* planning was complete.

# Bibliography

CM Apovian "The Obesity Epidemic – Understanding the Disease and the Treatment." N Engl J Med 2016; 374:177-179

PR Schauer et al "Bariatric Surgery versus Intensive medical therapy for Diabetes - 5-year outcomes." N Engl J Med 2017; 376:641-651

JS Yeh et al. "Obesity and Management of Weight Loss." N Engl J Med 2016; 375:1187-1189

E LeBlanc, C Patnode, E Webber, et al "Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force." JAMA. 2018;320(11):1172-1191 doi:10.1001/jama.2018.7777

SB Heymsfield and TA Wadden "Mechanisms, Pathophysiology, and Management of Obesity." N Engl J Med 2017;376:254-266

MW Schwartz, RJ Seeley, LM Zeltser, A Drewnowski, E Ravussin, LM Redman, RL Leibel "Obesity Pathogenesis." Endocr Rev. 2017 Aug 1;38(4):267-296.

AG Tsai et al, "Evidence of a Gap in Understanding, Obesity Among Physicians." Obesity, Science and Practice Online 1/12/18, DOI: 10/1002/asp4.416

MacLean PS, Rothman AJ, Nicastro HL, Czajkowski SM, Agurs-Collins T, Rice EL, Courcoulas AP, Ryan DH, Bessesen DH, Loria CM. The Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) Core Measures Project: Rationale and Approach. Obesity (Silver Spring). 2018 Apr;26 Suppl 2:S6-S15. doi: 10.1002/oby.22154.

D Al-Hamad, V Raman "Metabolic syndrome in children and adolescents." Transl Pediatr. 2017 Oct;6(4):397-407.

EA O'Connor, CV Evans, BU Burda, ES Walsh, M Eder, P Lozano "Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force." JAMA. 2017 Jun 20;317(23):2427-2444.

J Pratt, A Browne, N Browne, M Bruzoni, M Cohen, A Desai, T Inge, B Linden, S Mattar, M Michalsky, D Podkammeni, K Reichard, F Cody Stanford, M Zeller, J Zitsman "ASMBS Pediatric Metabolic and Bariatric Surgery Guidelines,2018" Surgery for Obesity and Related Diseases 2018: 14: 882-901.

G Srivastava, C Fox, A Kelly, A Jastreboff, A Browne, N Browne, J Pratt, C Bolling, M Michalsky, S Cook, C Lenders, C Apovian "Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity" Obesity 24 Jan 2019: 27: 190-204.

Cardel M, Jastreboff AM, Kelly A. Treatment of Adolescent Obesity in 2020. JAMA Insights. 2019 September 30.

Dennis M. Styne, Silva A. Arslanian, Ellen L. Connor, Ismaa Sadaf Farooqi, M. Hassan Murad, Janet H. Silverstein, Jack A. Yanovski, Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 102, Issue 3, 1 March 2017, Pages 709–757, <https://doi.org/10.1210/jc.2016-2573>



AcQasim, M Turcotte, RJ de Souza, MC Samaan, D Champredon, J Dushoff, JR Speakman, D Meyre "On the origin of obesity: identifying the biological, environmental and cultural drivers of genetic risk among human populations." *Obes Rev.* 2018 Feb;19(2):121-149.

N Hayba, SR Partridge, MM Nour, A Grech, M Allman Farinelli "Effectiveness of lifestyle interventions for preventing harmful weight gain among young adults from lower socioeconomic status and ethnically diverse backgrounds: a systematic review." *Obes Rev.* 2017 Nov 26.

GC Porter, K Laumb, T Michaud, F Brito, D Petreca, G Schwieger, T Bartee, KHK Yeary, PA Estabrooks "Understanding the impact of rural weight loss interventions: A systematic review and meta-analysis." *Obes Rev.* 2019 Jan 11. doi: 10.1111/obr.12825.

G Chen, A Doumatey, J Zhou, L Lei, A Bentley, O Fasanmade, G Okafor, B Eghan Jr, K Agyenim-Boateng, A Amoah, C Adebamowo, J Acheampong, T Johnson, J Oli, D Shriner, A Adeyemo, and C Rotimi1 "Genome-wide analysis identifies an African-specific variant in SEMA4D that is associated with Body Mass Index." *Obesity* 2017 April ; 25(4): 794–800. doi:10.1002/oby.21804.

National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Food and Nutrition Board, Roundtable on Obesity Solutions. "The Challenge of Treating Obesity and Overweight: Proceedings of a Workshop." Washington (DC): National Academies Press (US); 2017 Dec 21.

SB Heymsfield and TA Wadden "Mechanisms, Pathophysiology, and Management of Obesity." *N Engl J Med* 2017;376:254-266

JS Yeh et al. "Obesity and Management of Weight Loss." *N Engl J Med* 2016; 375:1187-1189

DA Williamson "Fifty Years of Behavioral/Lifestyle Interventions for Overweight and Obesity: Where Have We Been and Where Are We Going?" *Obesity (Silver Spring)*. 2017 Nov;25(11):1867-1875.

E LeBlanc, C Patnode, E Webber, et al "Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force." *JAMA*. 2018;320(11):1172-1191. doi:10.1001/jama.2018.7777

DE Wilfley, AE Staiano, M Altman, J Lindros, A Lima, SG Hassink, WH Dietz, S Cook "Improving Access and Systems of Care for Evidence-Based Childhood Obesity Treatment Conference Workgroup." *Obesity (Silver Spring)*. 2017 Jan;25(1):16-29.

C Baum, K Andino, E Wittbrodt, S Stewart, K Szymanski, R Turpin "The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA"

*Pharmacoeconomics*. 2015 Jul;33(7):643-53.

AS Chawla, CW Hsiao, MC Romney, R Cohen, F Rubino, P Schauer, P Cremieux "Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications." *Pharmacoeconomics*. 2015 Jul;33(7):629-41.

## Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

*This document was last updated January 4, 2023v2.*